Program 52: Kidney Cancer

肾癌治疗 项目总结/摘要 肾癌项目对肾脏肿瘤的分子基础进行创新的基础研究。 在目前的资助期内，科学工作的重点是确定有意义的生物标志物， 检测和预后，疾病生物学的潜在机制和新的治疗靶点， 各种肾癌人群，以及用于初步验证这些发现的改进的临床前模型。 该计划的具体目标是：1）识别和验证肾癌的新靶点，并建立 用于测试新药物的临床前模型; 2）识别反应和毒性的分子和生物学预测因子 3）利用计划和SPORE基础设施促进药物和器械开发;以及4） 确定增加风险的因素，预测肾癌的发展和复发。程序 有38名成员，代表7个DF/HCC机构和8个学术部门。在2014年， 经过审查的拨款资金中，来自国家癌症研究所的总费用为130万美元， 其他赞助商。在目前的资助期间，肾癌项目成员发表了742篇 癌症相关论文其中36%是机构间的，14%是方案内的，51%是 两个或多个DF/HCC成员之间的跨计划合作。总的来说，当计算一次时，27% 发展基金/总部合同委员会的出版物中有50%是方案间合作。

Kidney Cancer Program Project Summary / Abstract The Kidney Cancer Program performs innovative basic research into the molecular basis of kidney tumors. Scientific efforts within the current funding period have focused on identifying meaningful biomarkers for early detection and prognosis, underlying mechanisms of disease biology and novel therapeutic targets for the various kidney cancer populations, and improved preclinical models for preliminary validation of these findings. The specific aims of the program are to 1) Identify and validate novel targets in kidney cancer, and establish pre-clinical models for testing new agents; 2) Identify molecular and biologic predictors of response and toxicity to therapy; 3) Leverage Program and SPORE infrastructure to facilitate drug and device development; and 4) Identify factors that increase the risk, predict the development and recurrence of kidney cancer. The program has 38 members, representing seven DF/HCC institutions and 8 academic departments. In 2014 peer- reviewed grant funding attributed to the Program was $1.3 million in total costs from the NCI and $1.2 million from other sponsors. During the current funding period, Kidney Cancer Program members published 742 cancer-relevant papers. Of these 36% were inter-institutional, 14% were intra-programmatic, and 51% were inter-programmatic collaborations between two or more DF/HCC members. Overall, when counted once, 27% of DF/HCC publications were inter-programmatic collaborations.